Laureate Pharma, Inc. has entered into an agreement to produce Trubion Pharmaceuticals’ TRU-016, a novel protein for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Terms of the manufacturing agreement were not disclosed. “We are pleased that Trubion chose Laureate Pharma to manufacture TRU-016 for preclinical and clinical testing and we look forward to working with them on this novel product,” said Robert J. Broeze, Ph.D., presi...